Literature DB >> 25601024

Structural and biochemical characterization of VIM-26 shows that Leu224 has implications for the substrate specificity of VIM metallo-β-lactamases.

Hanna-Kirsti S Leiros1, Kine Susann Waade Edvardsen, Gro Elin Kjaereng Bjerga, Ørjan Samuelsen.   

Abstract

During the last decades antimicrobial resistance has become a global health problem. Metallo-β-lactamases (MBLs) which are broad-spectrum β-lactamases that inactivate virtually all β-lactams including carbapenems, are contributing to this health problem. In this study a novel MBL variant, termed VIM-26, identified in a Klebsiella pneumoniae isolate was studied. VIM-26 belongs to the Verona integron-encoded metallo-β-lactamase (VIM) family of MBLs and is a His224Leu variant of the well-characterized VIM-1 variant. In this study, we report the kinetic parameters, minimum inhibitory concentrations and crystal structures of a recombinant VIM-26 protein, and compare them to previously published data on VIM-1, VIM-2 and VIM-7. The kinetic parameters and minimum inhibitory concentration determinations show that VIM-26, like VIM-7, has higher penicillinase activity but lower cephalosporinase activity than VIM-1 and VIM-2. The four determined VIM-26 crystal structures revealed mono- and di-zinc forms, where the Zn1 ion has distorted tetrahedral coordination geometry with an additional water molecule (W2) at a distance of 2.6-3.7 Å, which could be important during catalysis. The R2 drug binding site in VIM-26 is more open compared to VIM-2 and VIM-7 and neutrally charged due to Leu224 and Ser228. Thus, the VIM-26 drug binding properties are different from the VIM-2 (Tyr224/Arg228) and VIM-7 (His224/Arg228) structures, indicating a role of these residues in the substrate specificity.
© 2015 FEBS.

Entities:  

Keywords:  Klebsiella pneumoniae; antibiotic resistance; drug binding site; metallo-β-lactamase; minimum inhibitory concentrations

Mesh:

Substances:

Year:  2015        PMID: 25601024     DOI: 10.1111/febs.13200

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  9 in total

1.  Biochemical Characterization of VIM-39, a VIM-1-Like Metallo-β-Lactamase Variant from a Multidrug-Resistant Klebsiella pneumoniae Isolate from Greece.

Authors:  Costas C Papagiannitsis; Simona Pollini; Filomena De Luca; Gian Maria Rossolini; Jean-Denis Docquier; Jaroslav Hrabák
Journal:  Antimicrob Agents Chemother       Date:  2015-09-14       Impact factor: 5.191

2.  Structural Insights into TMB-1 and the Role of Residues 119 and 228 in Substrate and Inhibitor Binding.

Authors:  Susann Skagseth; Tony Christopeit; Sundus Akhter; Annette Bayer; Ørjan Samuelsen; Hanna-Kirsti S Leiros
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

3.  Identification of a Stable Chromosomal Tandem Multicopy of blaVIM-63, a New blaVIM-2 Carbapenemase.

Authors:  Marina R Pulido; Andrea García-Montaner; Lorena López-Cerero; Felipe Fernández-Cuenca; José Gutiérrez-Fernández; Álvaro Pascual
Journal:  J Bacteriol       Date:  2022-06-27       Impact factor: 3.476

4.  Detection and Characterization of VIM-52, a New Variant of VIM-1 from a Klebsiella pneumoniae Clinical Isolate.

Authors:  Marie de Barsy; Paola Sandra Mercuri; Saoussen Oueslati; Eddy Elisée; Te-Din Huang; Pierre Sacré; Bogdan I Iorga; Thierry Naas; Moreno Galleni; Pierre Bogaerts
Journal:  Antimicrob Agents Chemother       Date:  2021-08-09       Impact factor: 5.191

5.  Virtual screening identifies broad-spectrum β-lactamase inhibitors with activity on clinically relevant serine- and metallo-carbapenemases.

Authors:  Francesca Spyrakis; Matteo Santucci; Lorenzo Maso; Simon Cross; Eleonora Gianquinto; Filomena Sannio; Federica Verdirosa; Filomena De Luca; Jean-Denis Docquier; Laura Cendron; Donatella Tondi; Alberto Venturelli; Gabriele Cruciani; Maria Paola Costi
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.379

6.  Crystal structures of VIM-1 complexes explain active site heterogeneity in VIM-class metallo-β-lactamases.

Authors:  Ramya Salimraj; Philip Hinchliffe; Magda Kosmopoulou; Jonathan M Tyrrell; Jürgen Brem; Sander S van Berkel; Anil Verma; Raymond J Owens; Michael A McDonough; Timothy R Walsh; Christopher J Schofield; James Spencer
Journal:  FEBS J       Date:  2018-11-23       Impact factor: 5.542

Review 7.  Molecular Mechanisms, Epidemiology, and Clinical Importance of β-Lactam Resistance in Enterobacteriaceae.

Authors:  Giulia De Angelis; Paola Del Giacomo; Brunella Posteraro; Maurizio Sanguinetti; Mario Tumbarello
Journal:  Int J Mol Sci       Date:  2020-07-18       Impact factor: 5.923

8.  Comparison of Verona Integron-Borne Metallo-β-Lactamase (VIM) Variants Reveals Differences in Stability and Inhibition Profiles.

Authors:  Anne Makena; Azer Ö Düzgün; Jürgen Brem; Michael A McDonough; Anna M Rydzik; Martine I Abboud; Ayşegül Saral; Ayşegül Ç Çiçek; Cemal Sandalli; Christopher J Schofield
Journal:  Antimicrob Agents Chemother       Date:  2015-12-14       Impact factor: 5.191

9.  Comprehensive exploration of the translocation, stability and substrate recognition requirements in VIM-2 lactamase.

Authors:  John Z Chen; Douglas M Fowler; Nobuhiko Tokuriki
Journal:  Elife       Date:  2020-06-08       Impact factor: 8.140

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.